Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
about
Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study.Emerging drugs in peripheral arterial diseaseArsenic exacerbates atherosclerotic lesion formation and inflammation in ApoE-/- miceIn utero arsenic exposure induces early onset of atherosclerosis in ApoE-/- miceAll cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.Which fasting triglyceride levels best reflect coronary risk? Evidence from the Turkish Adult Risk Factor Study.Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective.Efficacy of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for prevention of stroke.The role of fibric acid derivatives in the secondary prevention of coronary heart disease.Association of the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and concentrations of plasma lipids with high-density lipoprotein subclass distribution in the Chinese population.Recent developments in the treatment of hypertriglyceridemia.The role of fibric acids in atherosclerosis.Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Non-high density lipoprotein cholesterol versus low density lipoprotein cholesterol as a discriminating factor for myocardial infarctionAlcohol beverages and biochemical changes in blood.Low-density lipoproteins containing apolipoprotein C-III and the risk of coronary heart diseaseApolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy.Fat-1 transgenic cattle as a model to study the function of ω-3 fatty acidsEffects of stereospecific positioning of fatty acids in triacylglycerol structures in native and randomized fats: a review of their nutritional implications.Sex differences in HDL ApoC-III in American Indian youth.Identification of patients at high risk for adverse coronary events while awaiting routine coronary angioplasty.Angiographic trials of lipid-lowering therapy: end of an era?Disialylated apolipoprotein C-III proteoform is associated with improved lipids in prediabetes and type 2 diabetesRegression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.The role of hypertriglyceridemia in atherosclerosis.An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?Effect of dehydroepiandrosterone replacement on lipoprotein profile in hypoadrenal women.Pathologic findings in rabbit models of hereditary hypertriglyceridemia and hereditary postprandial hypertriglyceridemia.The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study.Association between apolipoprotein C3 Sst I, T-455C, C-482T and C1100T polymorphisms and risk of coronary heart disease.'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.Antiretroviral therapy in HIV-positive men is associated with increased apolipoprotein CIII in triglyceride-rich lipoproteins.Cost-effective treatment of coronary artery disease--the new imperative.Postprandial lipid metabolism in relation to coronary heart disease.Synthesis and biological evaluation of tert-butyl-5-methylpyrimidin-piperazine derivatives as anti-obesity agents.Association of hepatic lipase -514T allele with coronary artery disease and ankle-brachial index, dependence on the lipoprotein phenotype: the GENES study.Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation.The apolipoprotein epsilon2 allele and the severity of coronary artery disease in Type 2 diabetic patients.
P2860
Q21262011-A276DBBA-A3B2-4C08-96F5-A48781DE027EQ28195408-E81ECA5A-59B2-4FF3-BBFD-691118750B0BQ28392848-376D7327-1872-454C-AAA6-D41FECDBB91DQ28396600-BF36AC5D-BB32-428D-948E-8D8B41B66D41Q31101617-CEFC7F60-52FD-4F5A-B330-1589A055A678Q31982226-6E7208D8-F556-462E-8A48-625C587A1FAAQ33306319-B0445F81-7228-4D37-840B-6C32FE5327F1Q33815841-3F289B3B-D35B-4ABD-A0EC-1585D55639D9Q34027549-F9160375-11C9-4EFC-80C3-226F9FCD09C6Q34062910-C3026C57-4E95-4409-A3EF-2C965A6D7CEEQ34107158-D7DFD85D-1FE5-4DF2-8CC6-8F6EBA5B5872Q34109473-229928AB-33E1-42E5-97D2-7C484ABD1D73Q34441411-B7A5A3D7-E4CF-4AB3-A239-4B2E994C6C2CQ34480124-3FC8FCD2-B26C-4E55-AF27-D15B2777C567Q35613851-6BA28B06-155F-47F3-83E0-25CAD1C9A2F1Q35628166-2ADD3B7E-C142-43AF-BFCA-13815ACCEF4AQ35640331-382C8011-2618-4A99-AE8C-E262074B9277Q35704335-DA33E2DD-D413-4461-8188-3F862258BC64Q35939940-76F87012-5E10-462A-B57C-2A11D2967BDCQ36478598-A06576ED-3576-4569-BCA1-C2B2C1384A5DQ36816891-C8B959D0-1333-4EE6-9C25-1E31B97FC0D5Q36824071-817242BB-0892-43FC-8251-E0CE0E566621Q36843331-60B2AF8D-7BBC-4999-8DFD-85B5D76CC76EQ36913015-342368FA-F1ED-4B0A-9BDF-225D0C737B33Q36945217-360D7738-A85B-49DE-BCDA-0804C11CA0E1Q37059084-2263F830-24B0-4354-A20C-4E98CB4B0B58Q37189976-D82AB5FA-2481-4FA0-A587-7008D01767FFQ37253787-97B8271C-0135-498E-9DFD-9E757214EA57Q37311116-D7FA1449-D173-4458-A54D-E7AB34DAC5C1Q37456662-CEBBE5F4-B978-4241-BD0A-AADB1547D4D1Q37516902-093FCD38-0CD1-4658-98A7-AAE307D752E5Q37812146-312E4500-0AC1-4F2B-B4ED-7803804057ACQ40350510-50C28AD0-9339-4379-87CC-E78BD452F81DQ40389936-CCDB911D-9F9E-4973-8AEB-132121085ADEQ41157722-9FC5A210-C53E-4463-8DD6-82AF1438A1C6Q41571799-3DF6A6B2-87C8-401C-AA4A-4E7230FC93C2Q42835466-10DCE4A0-44AF-4C23-A69F-A8F3ADF175BAQ43099842-63FAD941-A612-49A2-97B6-0BD64E3C8407Q43225362-44D6272C-26D4-433E-B304-4C4AEA69D340Q43687465-4C0660C7-438B-4930-A807-D0D85C5D527A
P2860
Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh-hant
name
Triglyceride- and cholesterol- ...... ontrolled trial of lovastatin.
@en
Triglyceride- and cholesterol- ...... ontrolled trial of lovastatin.
@nl
type
label
Triglyceride- and cholesterol- ...... ontrolled trial of lovastatin.
@en
Triglyceride- and cholesterol- ...... ontrolled trial of lovastatin.
@nl
prefLabel
Triglyceride- and cholesterol- ...... ontrolled trial of lovastatin.
@en
Triglyceride- and cholesterol- ...... ontrolled trial of lovastatin.
@nl
P2093
P356
P1433
P1476
Triglyceride- and cholesterol- ...... ontrolled trial of lovastatin.
@en
P2093
Alaupovic P
Blankenhorn DH
Hemphill LC
Kramsch DM
P356
10.1161/01.CIR.90.1.42
P407
P577
1994-07-01T00:00:00Z